-+ 0.00%
-+ 0.00%
-+ 0.00%
Reported Saturday, Lilly Presents Eloralintide Phase 2 Exit Interview Results, With 74% Reporting Fewer Cravings, 52% Less Food Noise, Alongside EloraTZP, Retatrutide, Zepbound And Foundayo Data At ObesityWeek 2026
Share
Listen to the news
  • Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes
  • Results from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesity
  • People reported Foundayo was simple and easy to use in a new real-world evidence study, while patient-reported outcomes showed that participants treated with eloralintide reported reductions in food noise, food cravings and alcohol consumption
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending